Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)

 Eliem Therapeutics Inc ELYM announced interim results from its ongoing Period 1 trial of ETX-155 for big depressive disorder (MDD) and epilepsy. 
...